The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $163.58

Today's change-0.26 -0.16%
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $163.58

Today's change-0.26 -0.16%
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.

Amgen Inc down (U.S.)$0.26

Amgen Inc closed lower Friday, dropping (U.S.)$0.26 or 0.16% to (U.S.)$163.58. Over the last five days, shares have gained 0.75%, but are currently unchanged over the last year to date. Shares have outperformed the S&P 500 by 30.07% during the last year.

Key company metrics

  • Open(U.S.) $163.58
  • Previous close(U.S.) $163.84
  • High(U.S.) $164.57
  • Low(U.S.) $163.03
  • Bid / Ask-- / --
  • YTD % change+2.69%
  • Volume1,636,048
  • Average volume (10-day)2,463,480
  • Average volume (1-month)3,270,536
  • Average volume (3-month)3,243,204
  • 52-week range(U.S.) $113.01 to (U.S.) $173.60
  • Beta0.49
  • Trailing P/E22.07×
  • P/E 1 year forward17.07×
  • Forward PEG1.51×
  • Indicated annual dividend(U.S.) $3.16
  • Dividend yield1.93%
  • Trailing EPS(U.S.) $7.41
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+27.74%

Based on its net profit margin of 27.74%, Amgen Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.09%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue5,0335,3315,0315,180
Total other revenue--------
Total revenue5,0335,3315,0315,180
Gross profit4,0004,1484,1624,302
Total cost of revenue1,0331,183869878
Total operating expense3,0113,8723,5653,278
Selling / general / administrative1,0261,3271,2131,136
Research & development8941,2341,0181,018
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--9529226
Other operating expenses, total58119-6420
Operating income2,0221,4591,4661,902
Interest income (expense), net non-operating-252-261-269-282
Gain (loss) on sale of assets--------
Other--------
Income before tax1,8761,2861,3371,758
Income after tax1,6231,2941,2441,547
Income tax, total253-893211
Net income1,6231,2941,2441,547
Total adjustments to net income--------
Net income before extra. items1,6231,2941,2441,547
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,6231,2941,2441,547
Inc. avail. to common incl. extra. items1,6231,2941,2441,547
Diluted net income1,6251,2941,2441,547
Dilution adjustment2--0--
Diluted weighted average shares770773771768
Diluted EPS excluding extraordinary itemsvalue per share2.111.671.612.01
Dividends per sharevalue per share0.790.610.610.61
Diluted normalized EPSvalue per share2.111.682.252.27